Kiattipong / Shutterstock.com
LSIPR provides a look behind the scenes of Shire Pharmaceuticals, the Irish company valued at £46 billion by its acquirer Takeda.
Amid a spate of merger and acquisition activity in the life sciences space, in March 2018 came the news that Japan-based Takeda was considering plans to acquire biopharma company Shire.
Allergan had also put its hat in the ring for Shire, but in April, announced it wouldn’t move forward with a deal.
Takeda had its eyes on the prize—more than eight months and a series of revised proposals later, Takeda’s £46 billion ($59 billion) acquisition of Shire was approved by both sets of shareholders.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Shire Pharmaceuticals, Takeda, M&A, big data, statistics, patent prosecution, generic, brand, IP counsel, law firms, network, diversity, millennials